Last $3.59 USD
Change Today +0.01 / 0.28%
Volume 34.4K
MNOV On Other Exchanges
As of 5:20 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

medicinova inc (MNOV) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/16/14 - $4.80
52 Week Low
04/15/14 - $1.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDICINOVA INC (MNOV)

Related News

No related news articles were found.

medicinova inc (MNOV) Related Businessweek News

No Related Businessweek News Found

medicinova inc (MNOV) Details

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. Its product candidates include MN-166, a anti-inflammatory and neuroprotective agent, which has completed Phase 2 clinical trials for the treatment of neurological disorders; MN-221, a ß2-adrenergic receptor agonist that has completed Phase 2b clinical trails for the treatment of acute exacerbations of asthma; MN-001, an orally bioavailable small molecule compound, which has completed Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; and MN-029, a novel tubulin binding agent under development for the treatment of solid tumors. MediciNova, Inc. was founded in 2000 and is based in La Jolla, California.

11 Employees
Last Reported Date: 03/27/14
Founded in 2000

medicinova inc (MNOV) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $504.8K
Head of Japanese Office and Vice President
Total Annual Compensation: $293.6K
Chief Medical Officer
Total Annual Compensation: $293.6K
Compensation as of Fiscal Year 2013.

medicinova inc (MNOV) Key Developments

MediciNova Provides Update on Clinical Trial of MN-166 (Ibudilast) in ALS

MediciNova Inc. announced that the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) has enrolled 30 of the 60 subjects planned for participation. The trial is a randomized, double-blind, placebo-controlled study which includes a six-month treatment period followed by a six-month open-label extension. The study is evaluating several efficacy endpoints including functional activity (ALSFRS-R), respiratory function, muscle strength, and non-invasive ventilation (NIV) utilization in addition to monitoring the safety and tolerability of MN-166 60 mg/day versus placebo when administered in combination with riluzole in subjects with ALS. The principal investigator of the study is Benjamin Rix Brooks, MD, Director, Carolinas Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute in Charlotte, NC.

MediciNova Announces FDA Approval of Protocol for Phase 2 Trial of MN-001 in IPF

MediciNova Inc. announced that FDA (U.S. Food and Drug Administration) has approved the protocol for a clinical trial of MN-001 (tipelukast) for the treatment of moderate to severe IPF (idiopathic pulmonary fibrosis). Importantly, due to safety data from previous clinical studies of MN-001, FDA has agreed that MediciNova may proceed with a Phase 2 study as the first clinical trial of MN-001 in IPF. The IPF protocol was filed under MediciNova's open IND (Investigational New Drug Application) in FDA'sDivision of Pulmonary, Allergy, and Rheumatology Products (DPARP). FDA has granted orphan-drug designation to MN-001 for the treatment of IPF, which will provide MediciNova with seven years of marketing exclusivity if MN-001 is approved for IPF.

MediciNova Inc. Receives New Patent Covering MN-029 (Denibulin) Di-Hydrochloride in Japan

MediciNova Inc. announced that it has received a new patent from the Japanese Patent Office which covers MN-029 (denibulin) di-hydrochloride. The patent will expire no earlier than July 2032. The allowed claims cover a compound, pharmaceutical composition and method of treating certain cell proliferation diseases, including solid tumors, based on denibulin di-hydrochloride. MediciNova intends to use denibulin di-hydrochloride in future development. MN-029 is a novel, small molecule vascular disrupting agent (VDA) being developed for the treatment of solid tumor cancers. MediciNova licensed MN-029 from Angiogene Pharmaceuticals Ltd. Several preclinical pharmacology studies conducted by Angiogene Pharmaceuticals and MediciNova have assessed the mechanism of action and anti-tumor activity of MN-029 in vivo in rodent models of breast adenocarcinoma, colon carcinoma, lung carcinoma and KHT sarcoma. In these studies, MN-029 damaged poorly formed tumor blood vessels by weakening tumor blood vessel walls and causing leakage, clotting and eventual vascular shutdown within the tumor. These studies suggest that MN-029 acts quickly and is rapidly cleared from the body, which may reduce the potential for some adverse effects commonly associated with chemotherapy. Shutdown of tumor blood flow in tumor models was confirmed through the use of dynamic contrast-enhanced MRI. In two Phase I clinical studies conducted by MediciNova, MN-029 was well-tolerated at doses that reduced tumor blood flow.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNOV:US $3.59 USD +0.01

MNOV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MNOV.
View Industry Companies

Industry Analysis


Industry Average

Valuation MNOV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.6x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINOVA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at